BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 28, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 16, 2020
View Archived Issues
Encouraging preliminary phase I data announced for VAC-2 in NSCLC
Read More
Mucolytic agent MUC-031 has beneficial effects in cystic fibrosis model
Read More
Boehringer and OBT expand collaboration to discover additional selective cancer targets
Read More
Copanlisib plus rituximab leads to significantly prolonged PFS in CHRONOS-3 study
Read More
Phase III ASTRAL-2 and ASTRAL-3 studies of guadecitabine do not meet primary endpoint
Read More
FDA transfers IND application OST-HER2 to OS Therapies
Read More
FDA clears IND to initiate phase Ib/IIa study of AP-PA02
Read More
Positive data from ILIAD study of peginterferon lambda in outpatients with COVID-19
Read More
Ono Pharmaceutical synthesizes bispecific antibodies targeting CD19 and PD-1
Read More
New Toll-like receptor 2 antagonists identified at Neuropore Therapies
Read More
University of Barcelona discovers soluble epoxide hydrolase and acetylcholinesterase inhibitors
Read More
New pantothenate kinase 3 inhibitors identified at St. Jude Children's Research Hospital
Read More
Genfleet Therapeutics patents RIP-1 inhibitors
Read More
Investigator-initiated study of IONIS-PKK-LRx in patients with COVID-19 begins
Read More
Phase II trial of GLPG-1972 in osteoarthritis does not meet primary objective
Read More
MRT-5500 elicits neutralizing antibodies against SARS-CoV-2 in vivo
Read More
Unite and conquer approach finds shared weaknesses of coronaviruses
Read More
Vorinostat + sirolimus or everolimus shows encouraging activity and safety in r/r Hodgkin's lymphoma
Read More
BP-C2 mitigates radiation-induced gastrointestinal syndrome in mice
Read More
The cross-talk of SNAI2 and Hippo pathway in breast cancer metastasis
Read More
Exonate cleared to begin phase Ib/II evaluation of EXN-407 for diabetic macular edema
Read More
FDA approves Keytruda for adults with relapsed or refractory classical Hodgkin's lymphoma
Read More
Chitinase-3-like protein 1 identified as cystic fibrosis therapeutic target
Read More
Arch begins phase II trial of LSALT to prevent COVID-19-related complications
Read More
ImmunityBio receives FDA clearance for phase I trial of hAd5-COVID-19
Read More
FDA accepts IND for phase I/II study of Nuvation's NUV-422 in high-grade gliomas
Read More
